Show simple item record

dc.contributor.authorBARUT, Kenan
dc.contributor.authorKASAPÇOPUR, Özgür
dc.contributor.authorYildiz, Mehmet
dc.contributor.authorGulle, Bugra
dc.contributor.authorEker Omeroglu, Rukiye
dc.contributor.authorKoker, Oya
dc.contributor.authorSahin, Sezgin
dc.contributor.authorAdrovic, Amra
dc.date.accessioned2021-03-02T17:32:36Z
dc.date.available2021-03-02T17:32:36Z
dc.date.issued2020
dc.identifier.citationKoker O., Sahin S., Adrovic A., Yildiz M., BARUT K., Gulle B., Eker Omeroglu R., KASAPÇOPUR Ö., "A controversial topic in juvenile idiopathic arthritis: Association between biologic agents and malignancy", INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, cilt.23, ss.1210-1218, 2020
dc.identifier.issn1756-1841
dc.identifier.othervv_1032021
dc.identifier.otherav_d7994394-fd9b-43be-8997-3e059b702623
dc.identifier.urihttp://hdl.handle.net/20.500.12627/3991
dc.identifier.urihttps://doi.org/10.1111/1756-185x.13906
dc.description.abstractObjective Over the last 2 decades, the usage of biological agents in the treatment of juvenile idiopathic arthritis (JIA) has been a successful and promising approach in controlling disease activity and preventing chronic sequelae. However, there are ongoing concerns about the long-term safety data and side-effect profile. We aimed to present preliminary data on the incidence of malignancy in patients with JIA treated with biological agents versus the general population rates in Turkey. Method A single-center hospital-based cohort study was performed to analyze cancer occurrence among JIA patients treated with biologic agents during the observation period between January 2004 and May 2019. As reference data for direct standardization, age, gender, and calendar year-specific incidence rates from the Turkish cancer registry were used. The standardized incidence ratio (SIR, ratio of cancers observed to expected) was generated with 95% confidence intervals. Results The study sample consisted of 1023 JIA patients who had been treated with biologic or non-biologic agents. In the biologic-experienced group (n = 656), the mean age (at the study) was 16.7 +/- 5.6 years. The mean length of follow-up was 9.9 +/- 5.0 years. One cancer was detected within the observation period (SIR: 1.3, 95% CI: 0.06-6.3). The patient was an 18-year-old male who had previously received etanercept and tocilizumab until the diagnosis of the hematologic malignancy (SIR: 2.5, 95% CI: 0.1-12.6). Conclusion Patients treated with biologic agents appeared to have an increased rate of incident hematologic malignancy versus the general population in Turkey. However, before mentioning a clear causal relationship, other potential contributing factors should be taken into consideration.
dc.language.isoeng
dc.subjectİç Hastalıkları
dc.subjectİmmünoloji ve Romatoloji
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectROMATOLOJİ
dc.titleA controversial topic in juvenile idiopathic arthritis: Association between biologic agents and malignancy
dc.typeMakale
dc.relation.journalINTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
dc.contributor.departmentİstanbul Üniversitesi , İstanbul Tıp Fakültesi , Dahili Tıp Bilimleri Bölümü
dc.identifier.volume23
dc.identifier.issue9
dc.identifier.startpage1210
dc.identifier.endpage1218
dc.contributor.firstauthorID2273542


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record